NCT03672136

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients：An Exploratory Single-Arm Phase II Clinical Trail

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Shandong Cancer Hospital and Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients.

Detailed description

The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients, whether this regimen can improve PFS.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	Anlotinib	Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
OTHER	Concurrent Chemoradiotherapy	Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients

Timeline

• Start date: 2018-11-01
• Primary completion: 2019-11-01
• Completion: 2020-11-01
• First posted: 2018-09-14
• Last updated: 2018-09-14

Locations

1 site across 1 country: China